We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+10.19%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$125B
AUM Growth
+$7.74B
(+6.6%)
Cap. Flow
-$1.18B
Cap. Flow
% of AUM
-0.95%
Top 10 Holdings %
Top 10 Hldgs %
32.47%
Holding
4,267
New
79
Increased
1,134
Reduced
2,614
Closed
100
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Applovin
APP
|
+$80.1M |
| 2 |
Chevron
CVX
|
+$75.4M |
| 3 |
Robinhood
HOOD
|
+$52.2M |
| 4 |
Nutanix
NTNX
|
+$32.2M |
| 5 |
Datadog
DDOG
|
+$29.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$166M |
| 2 |
Apple
AAPL
|
+$150M |
| 3 |
NVIDIA
NVDA
|
+$148M |
| 4 |
HES
Hess
HES
|
+$72.3M |
| 5 |
ANSS
Ansys
ANSS
|
+$59M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.89% |
| 2 | Financials | 13.4% |
| 3 | Consumer Discretionary | 10.96% |
| 4 | Communication Services | 9.45% |
| 5 | Healthcare | 9.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PKST
2351
DELISTED
Peakstone Realty Trust
PKST
| $739K | ﹤0.01% |
56,364
-4,053
| -7% | -$54K |
|
2352
Zevra Therapeutics
ZVRA
$670M
| $737K | ﹤0.01% |
77,489
-5,732
| -7% | -$57.5K |
|
2353
Ardmore Shipping
ASC
$679M
| $736K | ﹤0.01% |
62,011
-1,688
| -3% | -$18.9K |
|
|
ESPR
2354
DELISTED
Esperion Therapeutics
ESPR
| $735K | ﹤0.01% |
277,491
+1,803
| +0.7% | +$3.49K |
|
|
NLOP
2355
Net Lease Office Properties
NLOP
$170M
| $733K | ﹤0.01% |
24,700
-1,329
| -5% | -$41.7K |
|
2356
Arcturus Therapeutics
ARCT
$212M
| $732K | ﹤0.01% |
39,742
-395
| -1% | -$6.34K |
|
2357
Alerus Financial
ALRS
$827M
| $731K | ﹤0.01% |
33,012
+749
| +2% | +$16.6K |
|
2358
Shore Bancshares
SHBI
$798M
| $731K | ﹤0.01% |
44,538
+1,525
| +4% | +$25.1K |
|
2359
Ambev
ABEV
$45.7B
| $728K | ﹤0.01% |
326,451
-85,530
| -21% | -$196K |
|
2360
Five Star Bancorp
FSBC
$1.13B
| $727K | ﹤0.01% |
22,567
-1,062
| -4% | -$33.4K |
|
2361
Phathom Pharmaceuticals
PHAT
$712M
| $726K | ﹤0.01% |
61,713
-2,844
| -4% | -$29.4K |
|
|
SVC
2362
Service Properties Trust
SVC
$1.04B
| $723K | ﹤0.01% |
53,386
-3,924
| -7% | -$53.2K |
|
|
RAPP
2363
Rapport Therapeutics
RAPP
$2.21B
| $721K | ﹤0.01% |
24,286
-663
| -3% | -$11.8K |
|
|
BCAX
2364
Bicara Therapeutics
BCAX
$1.84B
| $720K | ﹤0.01% |
45,619
-1,292
| -3% | -$14.5K |
|
2365
Solid Power
SLDP
$548M
| $716K | ﹤0.01% |
206,452
+9,675
| +5% | +$36.5K |
|
2366
Fortis
FTS
$28.3B
| $716K | ﹤0.01% |
14,115
-690
| -5% | -$33.9K |
|
2367
Vitamin Cottage Natural Grocers
NGVC
$648M
| $716K | ﹤0.01% |
17,893
+1,553
| +10% | +$60K |
|
2368
Equinor
EQNR
$95.8B
| $715K | ﹤0.01% |
29,345
-4,423
| -13% | -$111K |
|
2369
Emergent Biosolutions
EBS
$230M
| $713K | ﹤0.01% |
80,858
-3,167
| -4% | -$24.6K |
|
2370
Ultrapar
UGP
$6.47B
| $713K | ﹤0.01% |
173,922
-5,490
| -3% | -$18.7K |
|
|
OLP
2371
One Liberty Properties
OLP
$521M
| $713K | ﹤0.01% |
32,229
-1,481
| -4% | -$34.2K |
|
2372
Preformed Line Products
PLPC
$2.31B
| $711K | ﹤0.01% |
3,625
-72
| -2% | -$12.6K |
|
|
IMOS
2373
ChipMOS TECHNOLOGIES
IMOS
$1.91B
| $711K | ﹤0.01% |
37,085
-510
| -1% | -$8.99K |
|
2374
Precigen
PGEN
$2.56B
| $710K | ﹤0.01% |
215,769
+17,691
| +9% | +$49.9K |
|
2375
Rayonier Advanced Materials
RYAM
$609M
| $709K | ﹤0.01% |
98,174
+523
| +0.5% | +$2.69K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2025 Portfolio in Review
As of Q3 2025, RhumbLine Advisers held 4,267 positions worth $125B, up 6.6% from $117B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Trading was light in Q3 2025: portfolio turnover was 4.2%. RhumbLine Advisers opened 79 new positions and exited 100, leaving the 4,267-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 32% a quarter earlier, followed by Financials and Consumer Discretionary.
- RhumbLine Advisers's largest Q3 2025 buy was The Marzetti Company: 64,390 shares worth $11.1M.
- RhumbLine Advisers added most to Applovin in Q3 2025, an estimated $80.1M increase.
- RhumbLine Advisers's biggest Q3 2025 reduction was Microsoft, cutting an estimated $166M.
- RhumbLine Advisers fully exited Hess in Q3 2025, selling an estimated $72.3M.
- RhumbLine Advisers's ten largest holdings make up 32% of its $125B portfolio in Q3 2025.
- RhumbLine Advisers opened 79 new positions and closed 100 in Q3 2025.
- RhumbLine Advisers's portfolio value rose 6.6% quarter-over-quarter to $125B.
Based on RhumbLine Advisers's 13F filing for Q3 2025, filed 6 Nov 2025.